Legend Capital’s Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis

Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly...

Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022

Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO)...

Legend Capital’s Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical...

Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101...
EC Healthcare

EC Healthcare expects sales volume to increase 35% Y-o-Y to no less than HK$3...

EC Healthcare (the Company, which together with its subsidiaries is referred to as the Group, HKG: 2138), the largest non-hospital medical group in Hong...

Actual net profit exceeds FY2020’s level, China Biotech Services’ (08037) new growth drivers expected...

As the pandemic continued to affect the market, China Biotech Services (HKG: 8037), which owns one of the largest nucleic acid testing laboratories in...
SinoMab

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group, HKG: 3681), a Hong Kong-based biopharmaceutical company dedicated to the research,...
Avance Clinical

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization...

Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research...

Personalised Health Supplements Customised from Genetic Screening Results Offered on airasia Super App

Malaysian Genomics, airasia Super App, Speedoc and Unique Remedy Join Hands to Offer Health Solutions to airasia Super App's 51 Mil Users Malaysian Genomics...
EC Healthcare

EC Healthcare Opens New Multi-Service Flagship Medical Centre at Central and Advanced Imaging Centre...

EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group...

Malaysian Genomics Resource Centre Berhad Awarded Covid-19 Surveillance Contract

Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by...

Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant...

On March 31, the China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. (Recbio or the Company, HKG: 2179) went public and was...
Avance Clinical

Avance Clinical Announces New Office Opening in Melbourne

Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Melbourne to support its growing clinical...

Basecare Announces 2021 Annual Results: Overall Increase in Revenue and Gross Profit

Commercialization Driven by Innovative Platform Commitment to Create Full Reproductive Cycle Products Suzhou Basecare Medical Corporation Limited (Basecare or the Company, together with its...

Kingworld Medicines Sees 2021 Profit Soar 159% to RMB30.3 Million

Kingworld Medicines Group Limited (stock code: 01110.HK), a leading omni-channel enterprise providing world-famous greater health products, announced today its audited consolidated results for the...

Universal Medical Announces 2021 Annual Results: Business with Steady Promotion, Net Profit of Hospital...

Genertec Universal Medical Group Company Limited (the Company or Universal Medical, and together with its subsidiaries, the Group; HKG: 2666) is pleased to announce...

Kindstar Globalgene Announces FY2021 Annual Results, Revenue Increases to RMB930.67 Million

Focuses on Specialty Esoteric Testing Business Optimizes Vertical and Horizontal Industry Chain Deployment Kindstar Globalgene Technology, Inc. (Kindstar Globalgene or the Company, together with...

Essex Bio-Technology Announces 2021 Financial Results

Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million Essex Bio-Technology Ltd (Essex or the...

Sisram Medical Ltd Announces 2021 Record Annual Results

Strong Performance Led by Synergistic Development of Four Main Business Lines Under One Ecosystem Sisram Medical Ltd (the Company or Sisram, HKG: 1696; together with...

BBGI PCL (SET: BBGI) Debuts Shares on the SET March 17

Aiming to be a leading bio-product group with green innovation and sustainability BBGI PCL (SET: BBGI), a leader in the biofuel energy industry and...
SinoMab

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group, HKG: 3681), a Hong Kong-based biopharmaceutical company dedicated to the research,...